Parkinson's disease dementia (PDD) is a common and age-associated non-motor manifestation in patients with Parkinson’s disease. Pathologies associated with PD-D include Lewy body-type degeneration, cellular loss in subcortical nuclei and cortical Alzheimer-type pathology. Cholinesterase inhibitors such as rivastigmine and donepezil exert beneficial effects with moderate effect size.